US4767755A
Expired / Lapsed
US
⏱️ 0.0 years remaining
3-(acylaminomethyl)imidazo[1,2-a]pyridine derivatives and pharmaceutical compositions
Assignee: Synthelabo SA
•
Filing: 1987-02-04
•
Granted: 1988-08-30
•
Expires: 2007-02-04
Abstract
Abstract A compound which is a 3-(acylaminomethyl)imidazo[1,2-a]pyridine derivative of formula (I) ##STR1## or a pharmacologically acceptable acid addition salt is useful in therapy.
Inventors
- 👤 Pascal George
- 👤 Claudie Giron
- 👤 Jacques Froissant
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 23:14
CPC Classifications
C; C07; C07D; C07D471/00; C07D471/02; C07D471/04
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
293 words
A compound which is a 3-(acylaminomethyl)imidazo[1,2-a]pyridine derivative of formula (I) ##STR8## in which R 1 denotes hydrogen; linear or branched C 1 -C 4 alkyl; or benzyl: R 2 denotes linear or branched C 1 -C 6 alkyl; cyclohexyl; trichloromethyl; 1-propenyl; allyl; phenyl; 4-chlorophenyl; or benzyl: or R 1 and R 2 together denote a C 3 -C 5 aliphatic chain: X denotes halogen; C 1 -C 3 alkyl; methylthio; trifluoromethyl; optionally esterified carboxy of formula --COOR in which R denotes hydrogen or C 1 -C 6 alkyl; cyano; or optionally mono- or dialkylated aminocarbonyl of formula --CONR 3 R 4 in which R 3 and R 4 independently denote hydrogen or C 1 -C 4 alkyl or together denote a chain of formula --(CH 2 ) 2 --Z--(CH 2 ) 2 -- in which Z denotes a direct bond, oxygen, sulphur, or a divalent group of formula --CH 2 --, --NH-- or --N(C 1 -C 4 alkyl)--; alkylamino of formula NHR 5 in which R 5 denotes C 2 -C 6 alkyl; or dialkylamino of formula --NR 6 R 7 in which R 6 and R 7 independently denote C 2 -C 6 alkyl or together denote a chain of formula --(CH 2 ) 2 --Z--(CH 2 ) 2 -- in which Z denotes a direct bond, oxygen, sulphur, or a divalent group of formula --CH 2 --, --NH-- or --N(C 1 -C 4 alkyl)--: and Y denotes optionally esterified carboxy of formula --COOR 8 in which R 8 denotes hydrogen or C 1 -C 6 alkyl; cyano; or optionally mono- or dialkylated aminocarbonyl of formula --CONR 9 R 10 in which R 9 and R 10 independently hydrogen or C 1 -C 4 alkyl; or a pharmacologically acceptable acid addition salt.
Claim 2
Dependent Claim
293 words
A compound which is a 3-(acylaminomethyl)imidazo[1,2-a]pyridine derivative of formula (I) ##STR8## in which R 1 denotes hydrogen; linear or branched C 1 -C 4 alkyl; or benzyl: R 2 denotes linear or branched C 1 -C 6 alkyl; cyclohexyl; trichloromethyl; 1-propenyl; allyl; phenyl; 4-chlorophenyl; or benzyl: or R 1 and R 2 together denote a C 3 -C 5 aliphatic chain: X denotes halogen; C 1 -C 3 alkyl; methylthio; trifluoromethyl; optionally esterified carboxy of formula --COOR in which R denotes hydrogen or C 1 -C 6 alkyl; cyano; or optionally mono- or dialkylated aminocarbonyl of formula --CONR 3 R 4 in which R 3 and R 4 independently denote hydrogen or C 1 -C 4 alkyl or together denote a chain of formula --(CH 2 ) 2 --Z--(CH 2 ) 2 -- in which Z denotes a direct bond, oxygen, sulphur, or a divalent group of formula --CH 2 --, --NH-- or --N(C 1 -C 4 alkyl)--; alkylamino of formula NHR 5 in which R 5 denotes C 2 -C 6 alkyl; or dialkylamino of formula --NR 6 R 7 in which R 6 and R 7 independently denote C 2 -C 6 alkyl or together denote a chain of formula --(CH 2 ) 2 --Z--(CH 2 ) 2 -- in which Z denotes a direct bond, oxygen, sulphur, or a divalent group of formula --CH 2 --, --NH-- or --N(C 1 -C 4 alkyl)--: and Y denotes optionally esterified carboxy of formula --COOR 8 in which R 8 denotes hydrogen or C 1 -C 6 alkyl; cyano; or optionally mono- or dialkylated aminocarbonyl of formula --CONR 9 R 10 in which R 9 and R 10 independently hydrogen or C 1 -C 4 alkyl; or a pharmacologically acceptable acid addition salt.
Claim 3
Dependent Claim
20 words
A compound according to claim 1 wherein R 1 denotes hydrogen or methyl and R 2 denotes propyl or isobutyl.
Claim 4
Dependent Claim
15 words
A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically suitable excipient.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-08-30 | 1992-02-29 | 1992-08-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-08-30 | 1996-02-29 | 1996-08-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-08-30 | 2000-02-29 | 2000-08-30 | $7700.00 | Window Closed / Lapsed |